openPR Logo
Press release

Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

10-31-2023 03:15 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Relapsing Remitting Multiple Sclerosis Pipeline

Relapsing Remitting Multiple Sclerosis Pipeline

DelveInsight's, "Relapsing Remitting Multiple Sclerosis Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Relapsing Remitting Multiple Sclerosis Pipeline Report
• DelveInsight's Relapsing Remitting Multiple Sclerosis pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for Relapsing Remitting Multiple Sclerosis treatment.
• The leading companies working in the Relapsing Remitting Multiple Sclerosis Market include Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda, and others.
• Promising Relapsing Remitting Multiple Sclerosis Pipeline Therapies in the various stages of development include Ocrelizumab, Fingolimod, ALKS 8700, Dimethyl Fumarate, BG00002 (natalizumab), dirucotide, Rebif®, Copaxone®, and others.
• August 2023: Biogen announced a study of phase 4 clinical trials for peginterferon beta-1a. The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as measured by the Abbreviated Treatment Satisfaction Questionnaire to Medication (TSQM-9), at 12 weeks.
• September 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.

Request a sample and discover the recent advances in Relapsing Remitting Multiple Sclerosis Treatment Drugs @ Relapsing Remitting Multiple Sclerosis Pipeline Report- https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Relapsing Remitting Multiple Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Relapsing Remitting Multiple Sclerosis clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing Remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Relapsing Remitting Multiple Sclerosis Overview
The term multiple sclerosis refers to the distinctive areas of scar tissue (sclerosis - also called plaques or lesions) that result from the attack on myelin by the immune system. These plaques are visible using magnetic resonance imaging in the white and/or gray matter of people who have MS. Plaques can be as small as a pinhead or as large as a golf ball.

Find out more about Relapsing Remitting Multiple Sclerosis Therapeutics Assessment @ Relapsing Remitting Multiple Sclerosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Remitting Multiple Sclerosis Emerging Drugs Profile
• IMU-838: Immunic AG
• Tolebrutinib: Sanofi
• Telitacicept: RemeGen
• ANK700: Anokion

Relapsing Remitting Multiple Sclerosis Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Relapsing Remitting Multiple Sclerosis therapies. The Relapsing Remitting Multiple Sclerosis companies which have their Relapsing Remitting multiple sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Immunic.

Learn more about the emerging Relapsing Remitting Multiple Sclerosis Pipeline Therapies @ Relapsing Remitting Multiple Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Relapsing Remitting Multiple Sclerosis Pipeline Report
• Coverage- Global
• Relapsing Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsing Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Relapsing Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda, and others.
• Relapsing Remitting Multiple Sclerosis Pipeline Therapies- Ocrelizumab, Fingolimod, ALKS 8700, Dimethyl Fumarate, BG00002 (natalizumab), dirucotide, Rebif®, Copaxone®, and others.

Dive deep into rich insights for new drugs for Relapsing Remitting Multiple Sclerosis treatment, Visit @ Relapsing Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Relapsing-Remitting Multiple Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsing-Remitting Multiple Sclerosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. IMU-838: Immunic AG
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Telitacicept: RemeGen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ANK700: Anokion
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsing-Remitting Multiple Sclerosis Key Companies
21. Relapsing-Remitting Multiple Sclerosis Key Products
22. Relapsing-Remitting Multiple Sclerosis- Unmet Needs
23. Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers
24. Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion
25. Relapsing-Remitting Multiple Sclerosis Analyst Views
26. Relapsing-Remitting Multiple Sclerosis Key Companies
27. Appendix

For further information on the Relapsing Remitting Multiple Sclerosis pipeline therapeutics, reach out to Relapsing Remitting Multiple Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Published Important Links-

https://huggingface.co/dennydones9
https://www.jumpinsport.com/users/dennydones9
https://cybrvrs3.mn.co/posts/what-are-the-hot-flashes-in-prostate-cancer-market
https://myparea.mn.co/posts/44420239
https://comidarealkitchen.mn.co/posts/44420336
https://yizhanverse.mn.co/posts/what-is-the-hot-flashes-in-prostate-cancer-market-forecast
https://bookmarkswing.com/story16980789/hot-flashes-in-prostate-cancer-market
https://bookmarkspring.com/story10356297/hot-flashes-in-prostate-cancer-market-size
https://www.komoot.com/user/3809450162854
https://maphub.net/dennydones9
https://digitaldrip.mn.co/posts/44423215
https://ultraplus.mn.co/posts/44423326
https://veganxyz.mn.co/posts/44423488
https://ourclass.mn.co/posts/about-hot-flashes-in-prostate-cancer-market-size
https://diecast64.mn.co/posts/44423854
https://the-trifecta-network.mn.co/posts/44424109
https://talenthopper.mn.co/posts/44424433
https://thegameoflife-de.mn.co/posts/44424538
https://monvelli.mn.co/posts/44424617
https://mighty-men.mn.co/posts/44424691
https://jobs.recruitingblogs.com/employers/2384764-delveinsight
http://samus.vforums.co.uk/profile/dennydonesdi
http://supportskin.vforums.co.uk/profile/dennydonesdi
http://wwa.vforums.co.uk/profile/dennydonesdi
http://music.vforums.co.uk/general/2838/delveinsight
http://nuchinuxri.vforums.co.uk/profile/dennydones91021
http://raf.vforums.co.uk/profile/dennydonesdi
http://france.vforums.co.uk/Suggestions/1797/market-research-reports
http://thecir.vforums.co.uk/profile/dennydonesdi
http://lol.vforums.co.uk/profile/dennydonesdi
https://www.openlearning.com/u/havensmith-s2ry19/
https://dennydones9.cgsociety.org/profile
https://www.f6s.com/member/denny-dones
https://www.minecraftforum.net/members/dennydones9?__cf_chl_tk=ljVLvJPBSq9.mVHsoWgwPjJb0A23nSrkftR8IxJ5Wec-1697717482-0-gaNycGzNDTs
https://coderwall.com/p/4tufta/herpes-zoster-market-trends-and-developments-in-2023
https://midi.org/forum/20192-herpes-zoster-market-future-prospects-in-2023
https://tapas.io/ybhardwaj
https://photozou.jp/user/top/3328982
https://b.hatena.ne.jp/entry?url=https%3A%2F%2Fwww.delveinsight.com%2Freport-store%2Fherpes-zoster-market
https://www.thingiverse.com/dennydones9/designs
https://soundcloud.com/dennydones
https://experiment.com/users/dennydones9
https://lichess.org/@/dennydones9
https://www.nicovideo.jp/user/130955053
https://menwiki.men/wiki/Main_Page
https://historydb.date/wiki/2_Bonus_Paling_Penting_di_Agen_Sbobet88_Terpercaya
https://mozillabd.science/wiki/Main_Page
https://championsleage.review/wiki/Main_Page
https://timeoftheworld.date/wiki/Main_Page
https://funsilo.date/wiki/Main_Page
https://opensourcebridge.science/wiki/Main_Page
https://scientific-programs.science/wiki/Main_Page
https://lovewiki.faith/wiki/Main_Page
https://influence.co/dennydones9999
https://www.awwwards.com/dennydones9999/
https://www.producthunt.com/discussions/pharma-competitive-intelligence-tracking-services-navigating-the-pharmaceutical-landscape
https://forum.ngs.ru/profile/3132957/
https://zrzutka.pl/profile/delveinsight-295941
https://sound-social.com/story5059347/healthcare-competitive-intelligence-tracking-services
https://socialmarkz.com/story5419072/healthcare-competitive-intelligence-tracking-services
https://network-373.mn.co/posts/41603294
https://www.hogwartsishere.com/1562170/
https://www.renderosity.com/users/id:1400373
https://hitrecord.org/users/dennydones9999/records
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.atlasobscura.com/users/dennydones1
https://freedomlifestyle.mn.co/posts/41604435
https://socialmediainuk.com/story15310402/healthcare-competitive-intelligence-tracking-services
https://onlinedhan.mn.co/posts/41604571
https://skeleton-girls.mn.co/posts/41716585
https://network-89593.mn.co/posts/41716670
https://shaman-leaders.mn.co/posts/41716806
https://walkinvirtualclinics.mn.co/posts/41716883
https://machineintelligence.mn.co/posts/the-role-of-healthcare-partner-identification-services
https://vjudge.net/user/dennydones9999
https://yizhanverse.mn.co/posts/41717293
https://demo.plushforums.com/profile/18/denny-dones
https://www.sideprojectors.com/user/profile/69119
https://bookmarkstumble.com/story16655285/healthcare-partner-identification-services
https://bookmarkstime.com/story15535182/healthcare-partner-identification-services
http://baigasciedil.vforums.co.uk/profile/dennydones9999
http://weareone.vforums.co.uk/profile/dennydones9999
http://astarsuzuki.vforums.co.uk/profile/dennydones9999
http://proweb.vforums.co.uk/action/view_profile/user/dennydones9999
http://taresources.vforums.co.uk/action/view_profile/user/dennydones9999
http://gothicskin.vforums.co.uk/profile/dennydones9999
http://graphics.vforums.co.uk/profile/dennydones9999
http://clapecasna.vforums.co.uk/profile/dennydones9999
http://freuniontest.vforums.co.uk/profile/dennydones9999
http://whatwentwrong.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://system.vforums.co.uk/profile/dennydones9999
http://upsclan.vforums.co.uk/profile/dennydones999911
http://hairetevi.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://vfscomp2.vforums.co.uk/profile/dennydones9999
http://gamersgetaway.vforums.co.uk/profile/dennydones9999
http://surreyjobs.vforums.co.uk/profile/dennydones9999
http://support2.vforums.co.uk/profile/dennydones9999
http://swlsupport.vforums.co.uk/profile/dennydones9999
http://slipalimer.vforums.co.uk/profile/dennydones990099
http://art.vforums.co.uk/profile/dennydones990099
http://styles.vforums.co.uk/profile/dennydones990099
http://ghofertech.vforums.co.uk/profile/dennydones990099
http://dcdesign.vforums.co.uk/profile/dennydones990099
http://musicspot.vforums.co.uk/profile/dennydones990099
http://prov.vforums.co.uk/profile/dennydones990099
http://russell.vforums.co.uk/profile/dennydones990099
http://makethemes.vforums.co.uk/profile/dennydones990099
http://famousads.vforums.co.uk/profile/dennydones990099
http://pinkness.vforums.co.uk/profile/dennydones990011
http://elseandrew.vforums.co.uk/profile/dennydones99
http://suigacartsing.vforums.co.uk/profile/dennydones99
http://calanaera.vforums.co.uk/profile/dennydones99
http://legstudios.vforums.co.uk/action/view_profile/user/dennydones99
http://idirectory-old.vforums.co.uk/profile/dennydones99
http://skegness.vforums.co.uk/profile/dennydones99
http://futurexistence.vforums.co.uk/action/view_profile/user/dennydones99
http://codes.vforums.co.uk/profile/dennydones99
http://isgicaflo.vforums.co.uk/profile/dennydones99
http://profewovxi.vforums.co.uk/profile/dennydones99
http://zacsplace.vforums.co.uk/profile/dennydones99
http://sneeznavilas.vforums.co.uk/profile/dennydones99
http://coderspalace.vforums.co.uk/profile/dennydones991199
http://guide.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://rs2devolution.vforums.co.uk/action/view_profile/user/dennydones99
http://englishporcelain.vforums.co.uk/profile/dennydones99
https://scratchgram-2nd-instagram2.mn.co/posts/navigating-the-healthcare-landscape-with-competitive-intelligence-tracking-services
https://network-84066.mn.co/posts/42686849
https://www.canadavideocompanies.ca/author/dennydones1/
https://monvelli.mn.co/posts/42687788
https://fishjines.mn.co/posts/42688039
https://diecast64.mn.co/posts/42688112
https://mighty-men.mn.co/posts/42688183
https://team-clo.mn.co/posts/unveiling-the-power-of-healthcare-competitive-intelligence-tracking-services
https://stackoverflow.com/users/22614429/denny-dones?tab=profile
https://waarnemingen.be/users/791405/
https://keywebco.mn.co/posts/healthcare-competitive-intelligence-tracking-services-unveiling-the-future-of-healthcare-strategy

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated) here

News-ID: 3271200 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Relapsing

Relapsing Multiple Sclerosis Market Trends, Therapeutic Advances, and Growth Opp …
Relapsing Multiple Sclerosis (RMS) is a chronic, immune-mediated neurological condition characterized by episodes of acute neurological symptoms followed by periods of remission. Affecting millions globally, RMS imposes significant challenges on patients' quality of life, healthcare systems, and society at large. The Relapsing Multiple Sclerosis Market has gained substantial momentum as pharmaceutical companies, biotechnology firms, and healthcare providers focus on developing innovative disease-modifying therapies (DMTs) and personalized treatment strategies. With advancements
Global Relapsing-Remitting Multiple Sclerosis Market Research Report 2023-2029
Global Relapsing-Remitting Multiple Sclerosis Market: Driven factors and Restrictions factors The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones and current
Relapsing Refractory Multiple Myeloma Market Size in 7MM is expected to change f …
DelveInsight's "Relapsing Refractory Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Relapsing Refractory Multiple Myeloma, historical and forecasted epidemiology as well as the Relapsing Refractory Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover more about therapies set to grab major Relapsing Refractory Multiple Myeloma Market Share @ Relapsing Refractory Multiple Myeloma Market Size-
Relapsing-Remitting Multiple Sclerosis market: Complete Company Profiling of Dom …
" The Relapsing-Remitting Multiple Sclerosis global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key
Relapsing-Remitting Multiple Sclerosis market: Drivers, Threats, and Opportuniti …
" The Relapsing-Remitting Multiple Sclerosis global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key
Relapsing-Remitting Multiple Sclerosis Market detailed Strategies, Competitive L …
Relapsing-remitting multiple sclerosis (RRMS) is a kind of multiple sclerosis. It is the most common type of multiple sclerosis (MS), accounting for around 85% of source of diagnoses. Relapses of MS occur in people with RRMS with periods of remission occurring in between. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective layer around nerve fibers. Damage of